Tenofovir disoproxil fumarate (TDF), a nucleotide analogue reverse-transcriptase inhibitor is one of the most widely used antiretroviral medications and was approved by the US Food and Drug Administration for pre-exposure prophylaxis of primary human immunodeficiency virus (HIV) infection. Although there is evidence that TDF impairs the renal function, previous studies have not reported the concurrent assessment of kidney function among TDF use in Hispanics. Hispanics comprise the largest ethnic minority group in the US and experience disproportionate burden of diabetes and kidney disease. For this reason, as part of a Phase IV safety study on the use of TDF among HIV-infected Hispanic men who have sex with men, we conducted a pharmacovigilance retrospective study in El Paso, Texas, a predominantly Hispanic community. The specific objective of the study was to assess the effect that TDF has on estimated glomerular filtration rates among US Hispanics.